相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
Susan Branford et al.
CLINICAL CANCER RESEARCH (2007)
Congestive heart failure is a rare event in patients receiving imatinib therapy
Ehab Atallah et al.
BLOOD (2007)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge Cortes et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Ehab Atallah et al.
NATURE MEDICINE (2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gianantonio Rosti et al.
NATURE MEDICINE (2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Carlo Gambacorti et al.
NATURE MEDICINE (2007)
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Alan Hatfield et al.
NATURE MEDICINE (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini et al.
CANCER RESEARCH (2006)
In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations
Haruna Naito et al.
LEUKEMIA RESEARCH (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
S Kimura et al.
BLOOD (2005)
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
M Golemovic et al.
CLINICAL CANCER RESEARCH (2005)
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies
C Gambacorti-Passerini et al.
LEUKEMIA (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
NC Wolff et al.
BLOOD (2005)
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
K Gumireddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
H Kantarjian et al.
BLOOD (2004)
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
SW Cowan-Jacob et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
T O'Hare et al.
BLOOD (2004)
Chronic myelogenous leukemia: A review and update of therapeutic strategies
G Garcia-Manero et al.
CANCER (2003)
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon alpha-2b and low-dose cytosine arabinoside
G Garcia-Manero et al.
CANCER (2003)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
EA Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Practical management of patients with chronic myeloid leukemia receiving imatinib
MWN Deininger et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Lifetime risk for developing congestive heart failure - The Framingham Heart Study
DM Lloyd-Jones et al.
CIRCULATION (2002)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
OG Ottmann et al.
BLOOD (2002)
Imatinib mesylate and gray hair
G Etienne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Stevens-Johnson syndrome after treatment with STI571: a case report
LT Hsiao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
M Baccarani et al.
BLOOD (2002)
Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders
F Bonifazi et al.
BLOOD (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
分享论文
